Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Naïve Patients with HBeAg Positive Chronic Hepatitis B

The authors assessed the efficacy and antiviral resistance of 48-week clevudine therapy versus lamivudine in treatment of naïve patients with HBeAg positive chronic hepatitis B. In this retrospective study, a total of 116 HBeAg positive patients, who received 30 mg of clevudine once daily (n=53) or...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, In Hee, Lee, Seok, Kim, Seong Hun, Kim, Sang Wook, Lee, Seung Ok, Lee, Soo Teik, Kim, Dae Ghon, Choi, Chang Soo, Kim, Haak Cheoul
Formato: Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858834/
https://www.ncbi.nlm.nih.gov/pubmed/20436711
http://dx.doi.org/10.3346/jkms.2010.25.5.738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858834/
https://www.ncbi.nlm.nih.gov/pubmed/20436711
http://dx.doi.org/10.3346/jkms.2010.25.5.738

Ejemplares similares